vTv Therapeutics Inc.
VTVTHealthcare|Biotechnology|US
$21.03
-0.71 (-3.27%)
DCF Value
$10.43
Tangible Book / Share
$5.61
Cash / Share
$6.21
Clinical Trials (15)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06334133 Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes | Diabetes Mellitus, Type 1 | P3 | Active | 150 | RCT, Double-blind | Cadisegliatin 800 mg QD, Cadisegliatin 800 mg BID, Placebo |
| NCT02080364 Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease | Alzheimer's Disease | P3 | Terminated | 880 | RCT, Double-blind | Azeliragon, Placebo |
| NCT02916056 2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension) | Alzheimer's Disease | P3 | Terminated | 297 | Open-label | Azeliragon 5mg |
| NCT03980730 Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance | Alzheimer Disease | P2 | Terminated | 43 | RCT, Double-blind | Azeliragon, Placebo |
| NCT01474083 A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes | Type 2 Diabetes Mellitus | P1P2 | Completed | 248 | RCT, Double-blind | GK1-399 (formerly TTP399), GK1-399 (formerly TTP399), GK1-399 (formerly TTP399), Placebo |
| NCT01665352 A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes | Type 2 Diabetes Mellitus | P2 | Completed | 186 | RCT, Double-blind | TTP054, Placebo |
| NCT00909298 Left Ventricular Assist Device (LVAD) Specialized Centers of Clinically Orientated Research (SCCOR) Coagulation - Acute Intrinsic Pathway Antagonist (IPA) | Coagulation | P2 | Terminated | 2 | RCT, Double-blind | TTP889, Placebo |
| NCT02653599 A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes | Type 2 Diabetes Mellitus | P2 | Completed | 174 | RCT, Double-blind | TTP273, Placebo |
| NCT00119457 Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial) | Venous Thromboembolism, Embolism and Thrombosis | P2 | Completed | 300 | RCT, Double-blind | TTP889 |
| NCT07616206 Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems | Type 1 Diabetes (T1D) | P2 | Not Yet Recruiting | 40 | RCT, Double-blind | Cadisegliatin 800 mg QD, Placebo |
| NCT02405260 Add Glucokinase Activator to Target A1c | Diabetes Mellitus, Type 2 | P2 | Completed | 190 | RCT, Double-blind | TTP399 400 mg, TTP399 800 mg, Sitagliptin 100 mg, Placebo |
| NCT03335371 Evaluation of TTP399 in Patients With Type 1 Diabetes | Diabetes Mellitus, Type 1 | P1P2 | Completed | 115 | RCT, Double-blind | TTP399, TTP399, Placebo Oral Tablet |
| NCT00779519 Safety Study of the Inhibition of Agouti-related Protein (AgRP) for the Management of Obesity and Weight Loss | Obesity | P2 | Completed | 100 | RCT, Double-blind | TTP435, Placebo |
| NCT00939172 TTP607 in Refractory Solid Malignancies | Advanced Cancers, Lymphoma | P1 | Withdrawn | — | Open-label | TTP607 |
| NCT01548430 A Safety Study of TTP4000 in Subjects With Alzheimer's Disease | Alzheimer's Disease | P1 | Completed | 8 | RCT, Double-blind | TTP4000, Placebo |